Technology
Choose a subcategory:
a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta ( IL-1 beta), significantly reduced adverse co
These risks, including those related to inability to comply with NASDAQ's continued listing requirements; the declining and generally unstable nature of current economic conditions; the results of discovery research and pre-clinical testing
Other risks that may affect forward-looking information contained in this press release include the company's extremely limited capital resources, the possibility of being unable to obtain regulatory approval for Hedrin or its other product
Chelsea Therapeutics to Present at the ROTH 22nd Annual OC Growth Stock Conference on Wednesday, Mar
These risks and uncertainties include our need to raise operating capital, our history of losses, risks and costs of drug development, risk of regulatory approvals, our reliance on our lead drug candidates droxidopa and CH-4051, reliance on
For more information on Beacon Research, please visit http:// www. BeaconEquity. com Beacon Equity Disclosure DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT.
To read the entire report visit: http:// www.beaconequity. com/i/ BPAX See what investors are saying about BPAX at penny stock forum BeaconEquity. com is one of the industry's largest small-cap report providers.
To read the entire report visit: http:// www.stockpreacher. com/n/ GNBT See what investors are saying about GNBT at penny stock forum StockPreacher. com is a small-cap research and investment commentary provider.
Priorities for 2010- Report interim results from an 80 patient, Phase 2a trial of XOMA 052 in Type 2 diabetes with 60 patients on active drug and 20 patients on placebo- Conduct a 325 patient Phase 2b dose-ranging trial of XOMA 052 in Type
Athersys, Inc. Condensed Consolidated Balance Sheets ( In Thousands) ( Unaudited) December December 31, 31, 2009 2008 Assets Cash, cash equivalents and available-for-sale securities $ 26,382 $ 31,613 Other current assets 847 1,091 Equipment
For additional information about Nabi Biopharmaceuticals, please visit www.nabi. com CONTACT: Nabi Biopharmaceuticals Investor Relations 301-770- 3099 www.nabi. com
SOSUA BAY, Dominican Republic, March 11, 2010 ( GLOBE NEWSWIRE)- Proton Laboratories, Inc. President & CEO, Armando Casciati, announced today that the Company's updated information and disclosure statement has been filed on www.pinksheets.
HASBROUCK HEIGHTS, N.J., March 11, 2010 ( GLOBE NEWSWIRE)- Nymox Pharmaceutical Corporation announced today its financial results for the year ended December 31, 2009.